| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 9.187 | 43.807 | 41.938 | 17.746 | 23.158 | 31.453 | 29.894 | 15.434 | 15.460 | 10.766 |
| Total Income - EUR | 10.088 | 43.931 | 42.437 | 17.865 | 25.783 | 31.492 | 30.042 | 15.516 | 17.504 | 10.766 |
| Total Expenses - EUR | 23.409 | 50.521 | 41.147 | 16.577 | 19.879 | 15.610 | 14.900 | 15.187 | 13.237 | 10.313 |
| Gross Profit/Loss - EUR | -13.322 | -6.590 | 1.290 | 1.288 | 5.904 | 15.882 | 15.142 | 329 | 4.266 | 453 |
| Net Profit/Loss - EUR | -13.598 | -7.448 | 631 | 1.109 | 5.671 | 15.580 | 14.842 | 174 | 4.112 | 312 |
| Employees | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Placebo Prod Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.483 | 14.254 | 11.503 | 9.098 | 8.023 | 4.460 | 3.461 | 2.859 | 2.305 | 1.283 |
| Current Assets | 4.077 | 5.708 | 11.991 | 9.215 | 14.230 | 33.234 | 33.309 | 33.587 | 38.414 | 39.104 |
| Inventories | 0 | 0 | 0 | 0 | 2.592 | 2.542 | 2.486 | 2.494 | 2.486 | 2.472 |
| Receivables | 3.218 | 5.208 | 4.222 | 4.269 | 3.964 | 4.127 | 10.519 | 12.530 | 30.622 | 35.625 |
| Cash | 859 | 500 | 1.199 | 4.946 | 7.674 | 26.565 | 20.304 | 18.564 | 5.306 | 1.007 |
| Shareholders Funds | 3.011 | -4.468 | -3.761 | 14.806 | 20.191 | 35.388 | 34.210 | 34.491 | 38.498 | 38.594 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 4.549 | 24.791 | 27.447 | 3.727 | 2.196 | 2.539 | 2.559 | 1.955 | 2.222 | 1.826 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6201 - 6201" | |||||||||
| CAEN Financial Year |
6201
|
|||||||||
Comments - Placebo Prod Srl